Therapeutic cancer vaccines. The Journal of Clinical Investigation, September 2015, s. 3401–12. DOI: 10.1172/JCI80009. PMID 26214521.
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunology, Immunotherapy, March 2016, s. 327–39. DOI: 10.1007/s00262-016-1796-7. PMID 26861670.
HPV prophylactic vaccines: lessons learned from 10 years experience. Future Virology, 2015, s. 999–1009. DOI: 10.2217/fvl.15.60.
Development and implementation of papillomavirus prophylactic vaccines. Journal of Immunology, May 2014, s. 4007–11. DOI: 10.4049/jimmunol.1490012. PMID 24748633.
Development and implementation of papillomavirus prophylactic vaccines. Journal of Immunology, May 2014, s. 4007–11. DOI: 10.4049/jimmunol.1490012. PMID 24748633.
Therapeutic cancer vaccines. The Journal of Clinical Investigation, September 2015, s. 3401–12. DOI: 10.1172/JCI80009. PMID 26214521.
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunology, Immunotherapy, March 2016, s. 327–39. DOI: 10.1007/s00262-016-1796-7. PMID 26861670.
Development and implementation of papillomavirus prophylactic vaccines. Journal of Immunology, May 2014, s. 4007–11. DOI: 10.4049/jimmunol.1490012. PMID 24748633.
Development and implementation of papillomavirus prophylactic vaccines. Journal of Immunology, May 2014, s. 4007–11. DOI: 10.4049/jimmunol.1490012. PMID 24748633.